Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

Tatsuya Terasaki, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Hiroshi Imanaga, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koshi Akahane, Takeshi Inukai, Koichi Akashi, Takahiro Maeda

Blood (2023) 142 (Supplement 1): 1445.

https://doi.org/10.1182/blood-2023-182620

Published: 2023

Journal Articles

The XPO7/Npat Axis Inactivation Is a Therapeutic Vulnerability for TP53 -Mutated AML

Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Seishi Ogawa, Takahiro Maeda, Koichi Akashi

Blood (2023) 142 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2023-188986

Published: 2023

Journal Articles

CELMoD for ALL: an exciting prospect

Takahiro Maeda

Blood (2023) 142 (7): 614–615.

https://doi.org/10.1182/blood.2023020923

Published: 2023

Journal Articles

The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Seishi Ogawa, Koichi Akashi, Takahiro Maeda

Blood (2022) 140 (Supplement 1): 91–92.

https://doi.org/10.1182/blood-2022-168650

Published: 2022

Journal Articles

A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Hiroshi Imanaga, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Tatsuya Terasaki, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koichi Akashi, Takahiro Maeda

Blood (2022) 140 (Supplement 1): 5979.

https://doi.org/10.1182/blood-2022-164647

Published: 2022

Journal Articles

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda

Blood (2022) 139 (5): 748–760.

https://doi.org/10.1182/blood.2021012976

Published: 2022

Includes: Supplemental data

Journal Articles

Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda

Blood (2021) 138 (Supplement 1): 2257.

https://doi.org/10.1182/blood-2021-152027

Published: 2021

Journal Articles

Platelet Decrease and Efficacy of Platelet-Rich Plasma Return for Peripheral Blood Stem Cell Apheresis

Takahiro Shima, MD PhD, Teppei Sakoda, MD, Tomoko Henzan, MD, Yuya Kunisaki, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD, Toshihiro Miyamoto, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142316

Published: 2020

Journal Articles

Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia

Taro Tochigi, Toshihiro Miyamoto, Kiwamu Hatakeyama, Teppei Sakoda, Daisuke Ishihara, Hidetoshi Irifune, Takahiro Shima, Koji Kato, Takahiro Maeda, Takumi Ito, Hiroshi Handa, Koichi Akashi, Yoshikane Kikushige

Blood (2020) 135 (24): 2146–2158.

https://doi.org/10.1182/blood.2019003749

Published: 2020

Includes: Supplemental data

Journal Articles

A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells

Fumiaki Jinnouchi, Takuji Yamauchi, Ayano Yurino, Takuya Nunomura, Michitaka Nakano, Chika Iwamoto, Teppei Obara, Kohta Miyawaki, Yoshikane Kikushige, Koji Kato, Takahiro Maeda, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Katsuto Takenaka

Blood (2020) 135 (19): 1661–1672.

https://doi.org/10.1182/blood.2019002194

Published: 2020

Includes: Supplemental data

Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 910.

https://doi.org/10.1182/blood-2019-130694

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Fumihiko Nakao, MD, Takuji Yamauchi, MD PhD, Yuichiro Semba, MD PhD, Jumpei Nogami, PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 912.

https://doi.org/10.1182/blood-2019-129237

Published: 2019

Journal Articles

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 2516.

https://doi.org/10.1182/blood-2019-129372

Published: 2019

Journal Articles

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Kensuke Sasaki, MD, Kohta Miyawaki, MD PhD, Yuichiro Semba, MD PhD, Koji Kato, MD PhD, Jumpei Nogami, PhD, Takeshi Sugio, MD PhD, Toshihiro Miyamoto, MD PhD, Yoshikiyo Ito, MD PhD, Koji Nagafuji, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 375.

https://doi.org/10.1182/blood-2019-129625

Published: 2019

Journal Articles

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Kohta Miyawaki, MD PhD, Takuji Yamauchi, MD PhD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Hiroaki Miyoshi, MD PhD, Simon Osborne, PhD, Deborah Taylor, PhD, Koichi Ohshima, MD PhD, Koji Kato, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 396.

https://doi.org/10.1182/blood-2019-129613

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, MD PhD, Takuji Yamauchi, MD PhD, Fumihiko Nakao, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Luca Pinello, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 3784.

https://doi.org/10.1182/blood-2019-129623

Published: 2019

Journal Articles

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Takuji Yamauchi, MD PhD, Kohta Miyawaki, MD, Yuichiro Semba, MD PhD, Fumihiko Nakao, MD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Simon Osborne, PhD, Luca Pinello, PhD, Deborah Taylor, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 1390.

https://doi.org/10.1182/blood-2019-127047

Published: 2019

Journal Articles

Rational Targeting of a NuRD Sub-Complex for Fetal Hemoglobin Induction Following Comprehensive in Situ Mutagenesis

Mir Hossain, PhD, Falak Sher, PhD, Davide Seruggia, PhD, Vivien Schoonenberg, BS, Mitchel A. Cole, BS, Paolo Cifani, PhD, Laura Dassama, PhD, Claudio Macias-Trevino, BS, Matthew C. Canver, MD PhD, Ryo Kurita, PhD, Yukio Nakamura, MD PhD, Luca Pinello, PhD, Takahiro Maeda, MD PhD, Alex Kentsis, MD PhD, Stuart H. Orkin, MD, Daniel E. Bauer, MD PhD

Blood (2018) 132 (Supplement 1): 2342.

https://doi.org/10.1182/blood-2018-99-117043

Published: 2018

Journal Articles

Lymphoma Microenvironment Signature Predicts Clinical Outcomes in Diffuse Large B-Cell Lymphoma Patients

Kohta Miyawaki, MD, Takeshi Sugio, MD, Koji Kato, MD PhD, Kensuke Sasaki, MD, Hiroaki Miyoshi, MDPhD, Jon C. Aster, MD PhD, Frank C Kuo, MBBS, PhD, Koichi Ohshima, MDPhD, Takahiro Maeda, MDPhD, Koichi Akashi, MD PhD

Blood (2017) 130 (Supplement 1): 1474.

https://doi.org/10.1182/blood.V130.Suppl_1.1474.1474

Published: 2017

NARROW

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

The XPO7/Npat Axis Inactivation Is a Therapeutic Vulnerability for TP53 -Mutated AML

CELMoD for ALL: an exciting prospect

The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53 -Mutated AML

A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL

Platelet Decrease and Efficacy of Platelet-Rich Plasma Return for Peripheral Blood Stem Cell Apheresis

Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia

A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Rational Targeting of a NuRD Sub-Complex for Fetal Hemoglobin Induction Following Comprehensive in Situ Mutagenesis

Lymphoma Microenvironment Signature Predicts Clinical Outcomes in Diffuse Large B-Cell Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only